Skip to NavigationSkip to content

Business Services

Four perspectives from life sciences companies on multichannel engagement

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in their personal lives raise their expectations for business interactions. As more channels become available to HCPs, life sciences companies must adapt their approach to engaging with these customers.

Hear four perspectives from life sciences companies on how they are approaching multichannel engagement: 

NICE Chief Sir Andrew Dillon to step down in 2020

It’s the end of an era at the National Institute of Health and Care Excellence (NICE), the UK watchdog responsible for negotiating and authorising access to therapies on the National Health Service (NHS), as its Chief Executive Sir Andrew Dillon announces that he will step down from his role at the end of March next year.

Sir Dillon originally joined the organisation in 1999 as its founding Chief Executive and has held the role since.

Finding the needle in the haystack of rare disease

Published on 19/08/19 at 11:53am

Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory had failed in securing diagnosis for an ultra-rare disease patient. Romina Ortiz, Chief Operating Officer and Vice President, Patient Advocacy at the Institute explains how the platform could prove transformative in tackling the challenges of ultra-rare disease diagnosis.

Rare genetic diseases pose a challenge for diagnosis in three ways.

Top Ten most popular articles on Pharmafile.com this week!

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the use of bad data in getting its $2.1 million gene therapy Zolgensma approved by the FDA. While executives at Novartis subsidiary AveXis were kicked out, the US Senate demanded answers.

Britain call on companies to bid for 24 hour Brexit medicines shipping service contract

The British Government is calling on logistics companies to bid for a £25 million contract to run express freight containers carrying daily shipments of medicines into the UK after the Brexit deadline on 31 October.

The Department of Health and Social Care (DHSC) said the contract would form part of the UK’s contingency plans to deal with complications associated with Britain’s departure from the EU.

Executive shake-up at Novartis after Zolgensma data scandal

The AveXis executives that oversaw the marketing application for Zolgensma, the $2.1 million gene therapy at the centre of the faulty data scandal, are “no longer with the company” and “have not been involved” in any operations since early May, AveXis said.

Making things personal: Roche and personalised medicine

Published on 13/08/19 at 11:42am

Ann Costello, Global Franchise Lead, Centralised Solutions at Roche Diagnostics, discusses the increasing need for a personalised approach to patient care to tackle today’s health challenges, and how big data and the interplay between pharmaceuticals and diagnostics are key to driving progress in this area.

Can you explain the core idea behind personalised medicine and why it is increasingly gathering traction?

Top Ten most popular articles on Pharmafile.com this week!

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The Swiss firm’s integrity was called into question after it waited until it’s $2.1 million gene therapy had been approved before informing the US regulator of inaccuracies in its data.

Troy Robinson promoted to managing director of Chugai Pharma Europe

Published on: 06/08/19

Troy Robinson has been taken on as the new managing director of Chugai Pharma Europe. Mike Crosher will succeed him in his current role as managing director of Chugai Pharma UK.

Chugai Pharma Europe (CPE) has promoted Troy Robinson and Mike Crosher into the positions of managing director of CPE and managing director of the firm’s UK subsidiary, Chugai Pharma UK (CPU).

Living with a rare genetic neurodevelopmental disorder

Published on 05/08/19 at 12:36pm

Vaila Morrison’s daughter Eilidh was born with the ultra-rare condition KAT6A. As a designer and architect by profession, Vaila told Pharmafocus the ways in which having daughter with a disability transformed the way she sees the world.

What can you tell us about KAT6A?

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches